Compare Atomera Incorporated (ATOM) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atomera Incorporated vs Humana Inc — how do they compare? Atomera Incorporated trades at $5.57 (market cap $209.56M), while Humana Inc trades at $374.25 (market cap $46.31B). The key difference: Humana Inc is far larger — about 221× Atomera Incorporated's market cap, and Humana Inc pays a 0.92% dividend while Atomera Incorporated pays none. Which is the better fit depends on your goals.
| ATOM | HUM | |
|---|---|---|
Market Cap | $209.56M | $46.31B |
Sector | Technology | Health |
52-Week High | $12.11 | $409.42 |
52-Week Low | $1.99 | $163.67 |
Enterprise Value | $172.37M | $53.67B |
Dividend Yield | — | 0.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ATOM trades at $5.48, up 3.1% today, but faces significant fundamental challenges with a P/S ratio of 797.66 and deeply negative profitability metrics including a -78.7% gross margin and -9,742% net income margin. The company has missed earnings expectations for three consecutive quarters while technical indicators show bearish momentum with RSI signaling overbought conditions at 78.05. Recent news highlights progress in semiconductor technology licensing but financial performance remains weak.
Despite unanimous analyst buy ratings, ATOM presents high-risk exposure due to substantial losses, negative cash flow, and elevated valuation multiples. The semiconductor licensing business shows technological promise but requires significant revenue acceleration to justify current valuation. Near-term catalysts depend on commercial adoption breakthroughs while downside risk remains elevated given current financial metrics.
Humana (HUM) trades at $385.00, up 4.82% today, with a bullish technical outlook and analyst consensus price target of $399.53. Recent earnings beats in Q1 and Q2 2026, alongside revenue growth to $129.66 billion in 2025, support fundamentals, though net margins have compressed. The company is expanding its Medicaid business and targeting margin improvements by 2027.
The stock offers upside to consensus targets but faces risks from Medicare Advantage margin pressures and regulatory changes. Profitability trends are weak despite revenue growth, requiring successful cost management to meet 2028 targets. Institutional sentiment is mixed with a majority hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Atomera Incorporated
Atomera is a semiconductor materials engineering company. Its Mears Silicon Technology (MST) is a patented thin film that enhances transistor performance, power efficiency, and cost for global chip manufacturers.
Read more on ATOM →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
